
Vitrolife - Another quarter with improved organic growth

Vitrolife delivered a consecutive positive organic growth recovery with 7% organic growth in constant currencies (CER), this time without support from unusually large orders. The company is approaching the its targeted organic growth for most of business faster than we expected earlier. Our updated view is a base case valuation of SEK 260 (260), a Bull Case of SEK 400 (400), and a Bear Case of SEK 110 (110).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Vitrolife - Another quarter with improved organic growth](#)